Board of Directors
Our knowledgeable board is guiding us.
Charles Crocker is a principal of Crocker Capital, a private venture capital firm active in life sciences. He recently served as Chairman of the Board and CEO of BEI Technologies, Inc., a public, diversified technology company that he founded and was recently sold to Schneider Electric. He was Chairman, CEO, and founder of BEI Medical Systems, a public medical device company that was sold to Boston Scientific. He serves on the boards of Franklin Resources, Inc. and its subsidiaries (parent of the Franklin Templeton Funds), Mercator MedSystems, Inc., and Teledyne Technologies, Inc. He is Chair of the Franklin Compensation Committee and Chair of the Pope and Talbot Audit Committee.
Mr. Crocker has been Chairman of the Board of Children’s Hospital in San Francisco, Chairman of the Hamlin School’s Board of Trustees, President of the Foundation of the Fine Arts Museums of San Francisco, and a Trustee of the Buck Center for Research in Aging. He currently serves as a Trustee of the Mary A. Crocker Trust. Mr. Crocker received his B.S. degree from Stanford University and an M.B.A from the University of California, Berkeley.
Jim Erbs is Managing Director of Chetrum Capital, LLC, a private equity firm. Prior to founding Chetrum Capital, Mr. Erbs acquired, organized, led and sold a series of start-up and buyouts businesses, including SAF-T-MED, sold to Becton, Dickinson and Company and Laboratory Tops, Inc. sold to Metapoint Partners. Prior to leading his own companies, Mr. Erbs led turnarounds for Bain Capital and was a Manager at Bain & Company. Mr. Erbs currently serves as Chairman of Safety Socket, LLC. Mr. Erbs received his B.S. degree from the University of Texas at Austin and an M.B.A from the Harvard Business School.
John Maki is President and CEO of Vicus Therapeutics, LLC. Mr. Maki was previously Managing Director of Technology Directors Inc., an early-stage life science venture capital firm, Managing Director of Audax Group, a multi-asset class private equity firm, Principal of Bain Capital, a private alternative asset management company and a Consultant of Bain & Company, a business consulting firm. Mr. Maki currently serves on the boards of 3DMatrix, a medical device company and has been founding investor and/or board member of eleven life science companies. Mr. Maki also serves on the Board of Trustees of BIO NJ. Mr. Maki received his A.B. degree from Harvard University.
Arch Meredith is Managing Partner of Kite Hill Capital, a private venture capital firm. He is also Co-Founder of the Chroma Group and manages Chroma Group equity interests in Chroma Oil & Gas, Quantitative Imaging, and Vicus Therapeutics. Previously he was founder and CEO of TeleTix (acquired by Transamerica) and a principal at Salomon Brothers and McKinsey & Company. Mr. Meredith serves on the boards of Chroma Group, Quantitative Imaging, and New Scholars. Mr. Meredith received his B.A. degree from Stanford University and an M.B.A. from the Stanford Graduate School of Business.